

## ISBT Working Party on Platelet Immunobiology

### Business Meeting

June 1<sup>st</sup>, 2018, 1 pm – 2:15 pm, Metro Toronto Convention Center, Room 711

#### Attendees:

Australia: Gail Pahn (Stafford); Canada: Lucie Richard (Saint-Laurent), Lynnette Beaudin (Winnipeg); France: Rachel Petermann (Paris), Gérald Bertrand (Rennes); Germany: Ulrich J. Sachs (Giessen), Tamam Bakchoul (Tübingen); Israel: Lilach Bonstein (Haifa); Japan: Nelson H. Tsuno (Tokyo); Netherlands: Niubel Diaz Padilla (Utrecht); Norway: Maria Therese Ahlen (Tromsø); Oman: Shadhiya Al Khan (NN); Spain: Eduardo Muñiz Diaz (Barcelona), Núria Nogués (Barcelona); Sweden: Agneta Wikman (Stockholm), John Semple (Lund); United States: Brian Curtis (Milwaukee), Gayle Teramura (Seattle); Taiwan: Jen-Wei Chen (Taipeh).

#### Minutes:

#	Summary	Actions
1.	The business meeting started at 1 pm with a welcome from the chairmen.	-
2.	<u>Ulrich</u> gave an overview of the activities of the Working Party for the period 2017-2018 as reported to the ISBT Board of Directors earlier that year.	-
3.	<u>Lucie</u> gave a concise overview of the 19 <sup>th</sup> Platelet Immunology Workshop she and her team had organized on behalf of the WP. There were 29 registered participants from 17 countries from the Americas, Europe, Asia, and Australia. There were no African laboratories in the workshop. The workshop consisted of three proficiency-testing like exercises and three explorative/scientific exercises. Results were overall satisfying for HPA serology testing with the exception of HPA-15b and HPA-3a antibodies which were detected by less than 15% of the laboratories. <u>Brian</u> mentioned that this was most likely because the sample volume was too small for regular testing and labs may have performed tests with reduced specimen volumes. The HLA exercise gave good concordance for serology (78%) and for genotyping (78-82%). <u>Several members</u> felt that HLA serology and genotyping was inappropriate for a platelet workshop. For the HPA genotyping exercise, the consensus concordance was 99%. In the exploratory part, a commercial test was evaluated by 23 participants; it was concluded that a grey zone would be required since no sharp cut-offs could be identified in dilution series. In the second exercise, the platelet preparation with the aim of stabilizing HPA-3 epitopes on platelets largely failed; no conclusion could be drawn from this part. In the last exercise, moabs for immobilization of CD109 (HPA-15) were compared, with clones 1 and 4 being non-reactive in most laboratories, possibly as a result of shipping. No real conclusion from this specific exercise. The team has provided all participants with a detailed written report (a corrected version was distributed by Mazen on the 30 <sup>th</sup> May). <u>Nelson</u> and <u>Ulrich</u> expressed their explicit thanks to Lucie and her colleagues for their excellent work.	WP: to restructure the Workshop for the next period. This task was passed on to the new <u>Subcommittee on Quality</u> .

**Minutes (continued):**

<p>4.</p>	<p><u>Nelson</u> reported on the activities of the WP in Asia. The Asian Regional Working Party was installed in 2010 to ensure that specific aspects of the Asian population are met. <u>Nelson</u> demonstrated the differences for HPA-1, HPA-4 and CD36 as examples. Regional workshops were held in 2011 (Taipei, Taiwan) and 2013 (Kuala Lumpur, Malaysia), but not afterwards. Training courses were held during the ISBT Regional Meetings in 2010, 2013, 2015, and 2017. Details from the 2017 training course were presented; there were 9 participants from 6 different Asian countries trained in MAIPA. <u>Nelson</u> then outlined the importance of CD36 with respect to numerous antibody-mediated disorders including, FNAIT and TRALI.</p> <p>He concluded his presentation with two important questions: whether to held an Asian training course in cooperation with the Japanese Society, and whether or not to organize a wet workshop for the Asian countries.</p> <p>WP: members agreed on a training course in Japan and a new wet workshop for the Asian countries. <u>Brian</u> suggested an Asian committee. The WP members agreed to install an organization committee for Asia.</p>	<p><u>Nelson</u> to liaise with the Japanese society for details with regard to the training course.</p> <p><u>Nelson</u> to identify Asian ISBT members to sit on the Asian Workshop Organization Committee.</p>
<p>5.</p>	<p>Under miscellaneous, <u>Ulrich</u> suggested a list of all reference laboratories on the WP's ISBT web page.</p> <p>WP: members agreed.</p> <p><u>Ulrich</u> further suggested developing the web page into a clinically useful tool by providing platelet immunology-related information, which could be clinically relevant links as a start. WP: members agreed. <u>Maria Therese</u> to be the contact person for this project.</p> <p><u>Ulrich</u> also presented a project from the NIBSC in the UK who aim to produce an anti-HPA-15b minimum potency standard, with the project being already endorsed by the WHO. All WP members are encouraged to provide serum or plasma material if available. The WP was also asked to participate in the titration studies.</p> <p>WP: members agreed.</p>	<p><u>Ulrich</u> to send out an email to obtain consent from the labs.</p> <p><u>Ulrich</u> to contact ISBT web support.</p> <p><u>All members</u> to email Ulrich or lucy.studholme@nibsc.org if they have appropriate donors.</p>
<p>6.</p>	<p><u>Ulrich</u> gave an overview for the two subcommittees' work plans. The business meeting was closed at 2:15 pm and the WP split up in subcommittees.</p>	

Minute taker: Ulrich J. Sachs